EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results. 

CLASP TR Study: Resultados alentadores del tratamiento endovascular de la insuficiencia tricuspídea

The aim of this multicenter, prospective study was to assess the safety and efficacy of the PASCAL transcatheter tricuspid valve repair system. 

Primary end point was a composite of major cardiovascular events (MACE) at 30 days. Patients were followed up at 6 months, one, and five years. MACE included cardiovascular death, AMI, stroke, need of dialysis, severe bleeding, access site complications and device related intervention. 

It included 65 patients, mean age 77, mostly women (55%). STS score was 7.7%. Most patients were in functional class III/IV, 89% presented atrial fibrillation, 68% CABG or mitral valve replacement history and 14% had permanent pacemaker.  

Implantation success rate was 91%, while procedural success was 88%. The number of devices needed per patient was mostly 1 (46%) followed by 2 (41%). 

Read also: EuroPCR 2022 | The MITRA TUNE Registry.

After one year, 86% presented moderate TR or lower. Functional class also improved. 

Primary end point resulted 3.1% at 30 days and 16.9% at 1 year. Cardiovascular mortality was 3.1% and 7.7% respectively. There was 56% reduction in rehospitalization for cardiac failure. 

Conclusion

At 1 year, transcatheter tricuspid valve repair with PASCAL was shown safe and effective. There was significant reduction of TR, with improved functional class and quality of life. This study is still ongoing. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter tricuspid valve repair: CLASP TR study one year results. 

Reference: Rebecca Hahn et al. EUROPCR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

FRANCE TAVI Registry: Coronary Adverse Events After TAVI

Between 30% and 70% of patients undergoing transcatheter aortic valve implantation (TAVI) have coronary artery disease (CAD). However, the prognostic impact of CAD in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...